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Summary
Background The increasing prevalence of type 2 diabetes poses a major public health challenge. Population-based 
screening and early treatment for type 2 diabetes could reduce this growing burden. However, uncertainty persists 
around the beneﬁ ts of screening for type 2 diabetes. We assessed the eﬀ ect of a population-based stepwise screening 
programme on mortality.
Methods In a pragmatic parallel group, cluster-randomised trial, 33 general practices in eastern England were 
randomly assigned by the method of minimisation in an unbalanced design to: screening followed by intensive 
multifactorial treatment for people diagnosed with diabetes (n=15); screening plus routine care of diabetes 
according to national guidelines (n=13); and a no-screening control group (n=5). The study population consisted of 
20 184 individuals aged 40–69 years (mean 58 years), at high risk of prevalent undiagnosed diabetes, on the basis of 
a previously validated risk score. In screening practices, individuals were invited to a stepwise programme including 
random capillary blood glucose and glycated haemoglobin (HbA1c) tests, a fasting capillary blood glucose test, and a 
conﬁ rmatory oral glucose tolerance test. The primary outcome was all-cause mortality. All participants were ﬂ agged 
for mortality surveillance by the England and Wales Oﬃ  ce of National Statistics. Analysis was by intention-to-
screen and compared all-cause mortality rates between screening and control groups. This study is registered, 
number ISRCTN86769081.
Findings Of 16 047 high-risk individuals in screening practices, 15 089 (94%) were invited for screening during 
2001–06, 11 737 (73%) attended, and 466 (3%) were diagnosed with diabetes. 4137 control individuals were followed 
up. During 184 057 person-years of follow up (median duration 9·6 years [IQR 8·9–9·9]), there were 1532 deaths in 
the screening practices and 377 in control practices (mortality hazard ratio [HR] 1·06, 95% CI 0·90–1·25). We noted 
no signiﬁ cant reduction in cardiovascular (HR 1·02, 95% CI 0·75–1·38), cancer (1·08, 0·90–1·30), or diabetes-related 
mortality (1·26, 0·75–2·10) associated with invitation to screening.
Interpretation In this large UK sample, screening for type 2 diabetes in patients at increased risk was not associated 
with a reduction in all-cause, cardiovascular, or diabetes-related mortality within 10 years. The beneﬁ ts of screening 
might be smaller than expected and restricted to individuals with detectable disease.
Funding Wellcome Trust; UK Medical Research Council; National Health Service research and development support; 
UK National Institute for Health Research; University of Aarhus, Denmark; Bio-Rad.
Introduction
Type 2 diabetes poses a major public health challenge. 
The high proportion of undiagnosed cases of diabetes, 
the substantial number of patients with complications at 
clinical diagnosis, and the long latent phase of the disease 
are strong arguments for screening.1 Assessment of 
diabetes risk is currently included in the UK National 
Health Service (NHS) Health Checks programme for all 
individuals aged 40–74 years.2 Findings from studies 
nested in the ADDITION-Cambridge trial3 suggest that 
screening does not seem to be associated with psycho-
logical harm,4 nor does it falsely reassure individuals 
with negative results.5 However, uncertainty persists 
concerning the beneﬁ ts of population-based screening 
for type 2 diabetes, and more established screening tests 
such as mammography, with some suggesting that 
apparent beneﬁ ts are explained in part by overdiagnosis 
and improvements in treatment.6
Mortality reduction is a robust measure of the 
eﬀ ectiveness of a screening programme as shown for 
screening for prostate7 and cervical cancer.8 Mortality 
provides an overall assessment of the potential beneﬁ ts 
associated with population risk assessment, provision of 
risk information to patients and practitioners, invitation 
to testing, and early detection and treatment, as well as 
potential harms such as false reassurance. Identiﬁ cation 
of those at high risk of diabetes also provides oppor-
tunities for primary prevention of both diabetes and 
cardiovascular disease.9
Modelling studies suggest that a programme of screen-
ing for diabetes would reduce both diabetes-related and 
overall mortality,10–12 but these estimates de pend on 
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For the protocol see http://www.
mrc-epid.cam.ac.uk/Research/
Studies/ADDITION/index.html
several key assumptions that need conﬁ rmation in a 
randomised trial. We report mortality over a median 
9·6 years in a population-based cluster-randomised trial 
of screening in patients aged 40–69 years at high risk of 
having undiagnosed diabetes in general practices in 
eastern England.
Methods
Study design
ADDITION-Cambridge is a primary care-based screen-
ing and intervention study for type 2 diabetes. The study 
has been described in detail elsewhere;3,13 further details 
and the protocol are available. ADDITION-Cambridge 
consists of two phases: a pragmatic parallel group, 
unbalanced, cluster-randomised trial of screen ing; and a 
cluster-randomised trial comparing the eﬀ ects of 
intensive multifactorial therapy with routine care in 
individuals with screen-detected type 2 diabetes. We 
report the results from the trial of screening from the 
ﬁ rst phase of the study.
Ethics approval was granted by the Eastern Multi-
Regional Ethics Committee (02/5/54). Flagging of the 
records of individuals at high risk of having prevalent 
undiagnosed diabetes for mortality was approved under 
section 60 of the UK Health and Social Care Act 2001 
(Reference MR798).
Randomisation and masking
138 general practices in eastern England were invited by 
letter to participate, and 63 agreed, of which three served 
as pilots. Practices were stratiﬁ ed by the number of 
known diabetic patients (<160 and ≥160 patients) and 
their local referring district hospital. Randomisation was 
undertaken by a statistician using the method of 
minimisation. In the ﬁ rst stage of randomisation, 
33 recruited practices were allocated (1:3:3) to one of 
three groups: no screening (control; ﬁ ve practices), 
screening followed by intensive treatment of patients 
with screen-detected diabetes (IT; 15 practices), and 
screening plus routine care of patients with screen-
detected diabetes (RC; 13 practices). These practices are 
included in the main trial analysis of screening versus 
control presented here. One of the 28 screening practices 
dropped out before screening commenced because of 
logistical diﬃ  culties with identiﬁ cation of people at high 
risk. The need to achieve the required sample size of 
patients with screen-detected diabetes for the treatment 
trial warranted the uneven randomisation ratio with a 
disproportionate number of screening practices and a 
second stage of randomisation. 27 practices were sub-
sequently randomly assigned (1:1) to IT (n=14) and RC 
(n=13). The ﬁ nal group allocation after the two stages of 
randomisation included 28 practices to IT, 27 to RC, and 
ﬁ ve to control (no screening). A further six randomised 
practices (two IT and four RC) dropped out after 
recruitment, but before screening commenced because 
of other com mitments or unforeseen diﬃ  culties in 
setting up the practice-based screening programme. 
Results from all practices included in the ﬁ nal group 
allocation are also presented in a parallel cohort analysis. 
This design has the advantage of increasing the sample 
size for the comparison of screened versus control 
practices, but increases the possibility of confounding 
and selection bias. The investigators assessing outcomes 
and analysing data were masked to group assignment.
Eligibility criteria
Practices were recruited from September, 2001 to October, 
2002. From November, 2001 to April, 2003, we identiﬁ ed 
eligible individuals by searching the electronic medical 
records of 151 464 patients aged 40–69 years in 54 general 
practices for information about age, sex, body-mass index, 
and prescribed steroid and anti hypertensive medication. 
We used this information to calculate a previously 
validated score14 to predict the risk of undiagnosed 
diabetes. Practices were eligible to take part if they could 
provide data for calculation of the risk score for at least 
70% of their patients. Eligible par ticipants had a diabetes 
risk score of 0·17 or higher but were not known to have 
diabetes. This cutoﬀ  corresponds to the top 25% of the 
risk distribution in the participating practices. Infor-
mation about the diabetes risk score was withheld from 
practitioners and patients in the control practices. In 
screening practices, patients deemed un suitable for 
screening by their general practitioner were not invited 
for biochemical testing. Exclusion criteria were pregnancy, 
lactation, an illness with a likely prognosis of less than a 
year, or a psychiatric illness likely to restrict study 
involvement or invalidate informed consent.
Procedures
The invitation list for screening was deﬁ ned at the outset 
of the study; practices were asked to invite only the 
patients on the list that we provided. In the screening 
group (IT and RC), eligible individuals were sent a 
personal invitation from their general practitioner to 
attend their practice for stepwise screening including 
random capillary blood glucose and glycated haemo-
globin (HbA1c) tests and a fasting capillary blood glucose 
test, followed by a conﬁ rmatory oral glucose tolerance 
test undertaken in a local outpatient facility (ﬁ gure 1). 
Individuals attending the ﬁ nal glucose tolerance test 
stage also underwent assessment of cardiovascular risk 
factors including measurement of body-mass index, 
waist circumference, blood pressure, and blood lipids. 
Diagnosis of diabetes was based on the 1999 WHO 
criteria.15 Screening took place between January, 2002 
and March, 2006. Practice teams were notiﬁ ed of the 
results of all clinical and biochemical measures with a 
clear statement of whether or not the individual met 
diagnostic criteria for type 2 diabetes, and they then 
informed patients of the test results. Non-attendance was 
deﬁ ned as failure to attend the initial screening step after 
one reminder letter.
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Participants diagnosed with type 2 diabetes were 
subsequently managed according to the treatment 
regimen to which their practice was allocated: RC or IT. 
The characteristics of the interventions to promote 
intensive treatment have been described previously3 
(appendix). We aimed to educate and support general 
practitioners, practice nurses, and par ticipants in target-
driven management (with medication and promotion of 
healthy lifestyles) of hyperglycaemia, blood pressure, and 
cholesterol, similar to the stepwise regimen used in the 
Steno-2 study.16 Treatment targets and algorithms were 
based on trial data showing the beneﬁ ts of intensive 
treatment of cardiovascular risk factors in people with 
type 2 diabetes.16–20 In the RC group, participants with 
screen-detected diabetes re ceived usual diabetes care 
through the UK NHS based on current recommendations.21
The primary outcome was all-cause mortality; secondary 
outcomes were death from cardiovascular disease, cancers, 
and other causes, and diabetes-related death. All eligible 
partici pants were ﬂ agged for mortality surveillance by the 
England and Wales Oﬃ  ce of National Statistics, with 
unique NHS patient numbers. The Oﬃ  ce of National 
Statistics provided a copy of the death certiﬁ cate for 
deceased participants. The General Register Oﬃ  ce of 
Scotland and the Central Statistics Oﬃ  ce of Ireland were 
contacted to obtain the vital status of participants who 
moved to those areas. A trace of NHS records for current 
address in April, 2012 suggested that 1% of ADDITION-
Cambridge participants might have been lost to follow-up. 
Those lost to follow-up were assumed to be alive.
Deaths were coded into three categories (cardiovascular, 
cancer, and other) on the basis of the underlying cause 
of death. Cardiovascular death was deﬁ ned by an 
International Classiﬁ cation of Diseases, tenth edition 
(ICD-10) code in the range I00–I99, and cancer death by a 
code in the range C00–D48. We also noted whether 
diabetes was included anywhere on each death certiﬁ cate. 
This classiﬁ cation was independently done by an as-
sessor masked to randomisation group status. 50% of the 
deaths were classiﬁ ed by a second assessor with 98% 
agreement. Consensus was reached by discussion.
Statistical analysis
All analyses were pre-speciﬁ ed.3 Analyses were done 
on an intention-to-screen basis at the population level. 
All eligible high-risk individuals were considered in 
analyses irrespective of their participation in the 
screening programme (this population included non-
attenders and high-risk patients deemed unﬁ t for 
screening by their general practitioner). Comparison of 
baseline practice and patient characteristics between 
randomised groups was done with t tests for continuous 
data and χ² tests for categorical tests. To generate 
mortality rates, the number of person-years in the 
screening and control groups was calculated from the 
date of randomisation of each practice to the date of 
death or last information about the vital status of the 
patient. The earliest date of entry was Nov 21, 2001; 
deaths were conﬁ rmed up to Nov 28, 2011.
Hazard ratios (HR) comparing the screening (IT and 
RC) and control groups were estimated with a Cox 
proportional hazards model. Since randomisation was 
at the practice level, robust standard errors were calculated 
that take into account the two-level structure of the data 
Random capillary
blood glucose
≥11·1 mmol/L
5·5–11·0 mmol/L Fasting capillaryblood glucose
No diabetes
Stepwise screening tests in the
general practice
Conﬁrmatory tests
in outpatient
clinical research
facility
≥6·1 mmol/L
5·5–6·0 mmol/L
and capillary
HbA1c ≥6·1%
Standard 75g
oral glucose
tolerance test
<5·5 mmol/L<5·5 mmol/L
Capillary HbA1c
also measured
at this stage
Figure 1: ADDITION-Cambridge screening and diagnostic procedure
HbA1c=glycated haemoglobin.
138 practices invited to join the study 
63 practices agreed to participate
33 practices randomised
75 practices declined to participate
30 excluded
3 practices piloted screening
27 practices included in a second
stage of randomisation
1 excluded
1 practice withdrew before
identification of high-risk
individuals
27 practices randomised to screening
(14 practices to IT; 13 practices to RC)*
16 047 eligible participants; mean 594
(SD 340) per practice
15 089 participants invited for screening
11 737 participants attended screening
5 practices randomised to no-screening
(control)
4137 eligible participants; mean 827
(SD 228) per practice
27 practices included in the primary
outcome analysis (16 047 participants)
5 practices included in the primary
outcome analysis (4137 participants)
Figure 2: ADDITION-Cambridge trial proﬁ le
RC=screening followed by routine care of patients with screen-detected diabetes according to national guidelines. 
*IT=screening followed by intensive treatment of patients with screen-detected diabetes. 
See Online for appendix
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(individuals clustered within practices)22 and any potential 
correlation between individuals within practices. We 
calculated the intraclass correlation co eﬃ  cients (ICCs) 
for each mortality endpoint. We also did a parallel group 
cohort analysis that compared screening practices from 
both the ﬁ rst and second rounds of randomisation (n=49) 
with control practices (n=5). This analysis enabled us to 
include an additional 19 246 individuals in the comparison 
of screening and control practices. We did a sensitivity 
analysis to assess potential eﬀ ects of antecedent disease 
through exclusion of participants who died within 
3 months of ran domisation, and to examine the eﬀ ect of 
reclassifying individuals lost to tracking by the Oﬃ  ce of 
National Statistics as deceased. We also undertook an 
analysis that compared mortality between attenders and 
non-attenders for screening. All analyses were done with 
Stata (version 12.1).
The study sample size was originally estimated to 
quantify the eﬀ ectiveness of intensive treatment in 
screen-detected patients via detection of a 20% relative 
diﬀ erence in the UK Prospective Diabetes Study 
(UKPDS) modelled 10-year risk of cardiovascular disease 
between patients with screen-detected diabetes in the IT 
and RC groups.3
This trial is registered, ISRCTN86769081.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the study data and ﬁ nal responsibility for 
submission for publication.
Results
Figure 2 shows the trial proﬁ le. Practices that declined 
to take part were similar to those who agreed to take 
part in terms of list size, prevalence of undiagnosed 
diabetes, number of general practitioner or nurse whole 
time equivalents, and the Index of Multiple Deprivation 
score23 (data not shown). However, participating prac-
tices had a smaller list size, lower crude diabetes 
prevalence, and fewer general practitioner or nurse 
whole time equivalents than did the average English 
practice (data taken from the UK National Primary Care 
Database). Furthermore, the Index of Multiple Depri-
vation scores for ADDITION-Cambridge practices 
(median [IQR] 11·7 [7·1–17·7]) suggested that they 
served less deprived communities than the average 
English practice (21·3 [12·3–36·1]).
Table 1 shows the baseline characteristics of practices 
and participants. The screening and control groups 
were well balanced except for participant age and the 
proportion of participants prescribed steroids, which 
were slightly higher in the screening group.
After the ﬁ rst stage of randomisation, 20 184 individuals 
(median age 59 years; IQR 53–65) were eligible for 
screening on the basis of their diabetes risk score in the 
32 participating practices (screening and IT 14 practices; 
screening and RC 13 practices; no-screening control ﬁ ve 
practices). Of 16 047 eligible people in the screening 
group, 15 089 (94%) were invited and 11 737 (73%) 
attended the ﬁ rst stage of screening. 466 participants 
(3% of those eligible for screening) were diagnosed with 
diabetes. 4137 individuals were in the no-screening 
control group.
No screening (control) Screening (intervention)
Practices
Number 5 27
Practice list size 9351 (3038) 7271 (582)
Unadjusted prevalence of diabetes (%) 3·3% (0·8) 3·0% (1·0)
General practitioner whole time equivalents 4·8 (2·0) 3·8 (1·6)
Nurse whole time equivalents 2·1 (0·8) 2·0 (0·8)
Index of multiple deprivation score* 16·1 (9·0) 12·9 (7·7)
Participants
Number 4137 16 047
Age (years) 57·9 (7·8) 58·2 (7·7)
Men, n (%) 2641 (63·9%) 10 260 (63·9%)
BMI (kg/m²) 30·6 (4·6) 30·5 (4·6)
Diabetes risk score median (IQR) 0·34 (0·24–0·51) 0·35 (0·24–0·52)
Prescribed antihypertensive medication, n (%) 1853 (44·8%) 7372 (45·9%)
Prescribed steroids, n (%) 154 (3·7%) 866 (5·4%)
Data are mean (SD) unless otherwise indicated. BMI=body-mass index. *The Index of Multiple Deprivation combines 
a number of indicators, chosen to cover a range of economic, social, and housing issues, into one deprivation score 
for each small area in England. This score allows each area to be ranked relative to one another according to their level 
of deprivation. A high Index of Multiple Deprivation score indicates a high level of deprivation.
Table 1: Baseline characteristics of practices and eligible individuals at high risk of undiagnosed diabetes 
in the ADDITION-Cambridge trial
No-screening control group Screening group Hazard ratio (95%CI)*
Number 
of deaths
Person-years 
of follow-up
Rate per 1000 
person-years (95% CI)
Number 
of deaths
Person-years 
of follow up
Rate per 1000 
person-years (95% CI)
All-cause mortality 377 38 126 9·89 (8·94–10·94) 1532 145 930 10·50 (9·99–11·04) 1·06 (0·90–1·25)
Cardiovascular mortality 124 38 126 3·25 (2·73–3·88) 482 145 930 3·30 (3·02–3·61) 1·02 (0·75–1·38)
Cancer mortality 169 38 126 4·43 (3·81–5·15) 697 145 930 4·78 (4·43–5·14) 1·08 (0·90–1·30)
Other causes of death 84 38 126 2·20 (1·78–2·73) 353 145 930 2·42 (2·18–2·68) 1·10 (0·87–1·39)
*Accounting for clustering.
Table 2: Incidence of death by study group and hazard ratios for mortality in the ADDITION-Cambridge trial 
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Median duration of follow-up was 9·6 years 
(IQR 8·9–9·9; 184 057 person-years). From November, 
2001 to November, 2011, there were 1532 deaths in the 
screening group and 377 in the control group (table 2). 
The ICC values were very small (all-cause mortality 0·007; 
cardiovascular disease mortality 0·024; cancer mortality 
0·0000011; diabetes-related mortality 0·000015). The 
most common cause of death was cancer (table 2). All-
cause mortality did not diﬀ er signiﬁ cantly between the 
screening and the control groups (HR 1·06, 95% CI 
0·90–1·25; p=0·46; ﬁ gure 3). Sensitivity analyses showed 
that the results were not aﬀ ected by the exclusion of 
people (n=24) who died within 3 months of randomisation 
(1·07, 0·90–1·26; p=0·44). The proportion of individuals 
lost to Oﬃ  ce of National Statistics tracking was equally 
distributed between trial groups; results were not aﬀ ected 
if these individuals were assumed to have died (data not 
shown). We noted no signiﬁ cant diﬀ erence between 
groups in cardiovascular mortality, cancer mortality, or 
other causes of death (table 2). Diabetes was listed among 
other causes of death in 91 individuals (75 in the screening 
group and 16 in the control group). There was no 
signiﬁ cant diﬀ erence between groups in diabetes-related 
mortality (1·26, 0·75–2·10). None of these estimates were 
aﬀ ected by adjustment for IT or RC trial group (data not 
shown). Compared with attenders, non-attenders for 
screening were younger, more obese, more likely to be 
men, less likely to be taking antihypertensive drugs, and 
had a higher all-cause mortality (adjusted HR 2·01, 
95% CI 1·74–2·32).
In the parallel group cohort analysis, there were 
2769 deaths in the 49 screening practices from 
November, 2001 to November, 2011. Mortality rates 
compared with the no-screening control group were 
similar to the trial analysis results presented above (data 
not shown). The most common cause of death was 
cancer. We noted no signiﬁ cant diﬀ erences between the 
screening and the control groups for all-cause mortality 
(HR 0·98, 95% CI 0·84–1·14), cardiovascular mortality 
(0·92, 0·70–1·22), cancer mortality (1·00, 0·84–1·20), 
other causes of death (1·00, 0·80–1·25), or diabetes 
related mortality (0·97, 0·58–1·61).
Discussion
In this large, population-based UK sample, all-cause mor-
tality over a median 9·6 years was not reduced by one 
round of screening for type 2 diabetes in people at high 
risk of prevalent undiagnosed diabetes. Similarly, invitation 
to screening was not associated with a reduction in 
cardiovascular, cancer, diabetes-related, or other causes of 
death. Results from the parallel cohort analysis were 
similar to those from the main trial analysis, suggesting 
that population-based screening for diabetes is not asso-
ciated with a reduction in all-cause, cardiovascular, or 
diabetes-related mortality within 10 years in this age group.
Modelling studies indicate that a programme of 
screening for diabetes every 3–5 years would reduce 
diabetes-related mortality in Taiwan by 26–40%,10,11 and 
would prevent up to ﬁ ve deaths per 1000 people in the 
USA.12 An examination of the mortality experience of the 
Ely cohort24 suggested that individuals who were invited 
to diabetes screening every 5 years between 1990 and 
1999 had a non-signiﬁ cant 21% lower all-cause mortality 
than did individuals who were not invited to screening. 
However, the parameters used in these non-randomised 
studies diﬀ ered from the characteristics of the screening 
programme in our study—eg, the frequency and nature 
of the screening tests, length of follow-up, and population 
subgroups in which screening was undertaken. The 
ﬁ nding of a higher risk of mortality in those not attending 
an appointment for screening compared with those who 
attended accords with ﬁ ndings from other population-
based screening programmes,25 and is likely to indicate 
healthy volunteer bias and exclusion of unhealthy 
individuals by general practitioners.
There are several possible explanations for the lack 
of diﬀ erence in mortality recorded in this trial. There 
might have been a dilution of the eﬀ ect of screening. 
There is ongoing ad-hoc opportunistic screening for 
type 2 diabetes in primary care in the UK, following 
recommendations from organisations such as Diabetes 
UK.26 Opportunistic screening, combined with 27% 
non-attendance for screening and less than 100% 
sensitivity at each stage of the screening programme, 
could have contributed to the fairly low yield of screen-
detected patients. However, evidence suggests that the 
extent of opportunistic screening is limited in the UK.27 
There has been a continuing improvement in the 
detection and management of cardiovascular disease 
risk factors including diabetes in UK primary care,28 an 
occurrence enhanced by the Quality and Outcomes 
Framework system of remuner ation for general 
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Figure 3: Cumulative incidence of death in the screening and no screening control groups in the 
ADDITION-Cambridge trial
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practitioners.29 This improvement might have con-
tributed to the mortality in high-risk individuals in the 
control group being 50% lower than expected on the 
basis of observational data from the Netherlands.30 
Furthermore, the prevalence of undiag nosed diabetes 
might have been previously over estimated.
Evidence is growing for the beneﬁ t of intensive 
treatment of risk factors early in the course of the 
disease.31 Results from ADDITION-Europe, a cluster-
randomised trial of intensive, target-driven manage ment 
of screen-detected patients, showed that individuals 
diagnosed and treated earlier had a mor tality experience 
that was similar to that reported for people of the same 
age without diabetes in the general population in 
Denmark.32 However, although earlier detection could 
beneﬁ t the few people diagnosed with diabetes, the 
proportion might have been too small to aﬀ ect population 
mortality in ADDITION-Cambridge. In the event of a 
lower than expected prevalence of undiagnosed diabetes, 
eﬀ ects of screening on mortality might therefore be 
limited. In populations with higher rates of undiagnosed 
prevalent diabetes, the eﬀ ects of screening on mortality 
could be larger. However, recent estimates of a fairly 
short lead time (around 3 years) between detection by 
screening and clinical diagnosis suggest that the beneﬁ ts 
of screening might have been overestimated.33
For prostate cancer, the eﬀ ect of screening on 
population mortality is established largely by the eﬀ ects 
of earlier diagnosis and treatment. Identiﬁ cation of 
individuals at high risk of developing diabetes oﬀ ers 
other opportunities for health promotion. Eﬀ ects on 
mortality might have been greater if cardiovascular 
disease risk factors had been assessed alongside glucose 
at the initial screening appointment, as proposed in the 
UK Health Checks programme,2 if lifestyle advice had 
been provided with risk information to participants who 
screened negative for diabetes at any stage, and if uptake 
of screening had been higher. Only one screening round 
was undertaken. Repeated screening might be asso-
ciated with greater beneﬁ ts, although response rates 
could fall over time and costs would be greater. Finally, 
population-based screening for type 2 diabetes might be 
associated with little beneﬁ t at the population level (in 
all those invited to screening). An individual high-risk 
approach to reducing the burden of type 2 diabetes may 
therefore need to be complemented by a population-
based strategy targeting the underlying determinants of 
disease risk.
Diabetes was stated as cause of death on only 90 death 
certiﬁ cates. The underreporting of diabetes-related mor-
tality could have led to an underestimate of the eﬀ ect of 
screening.34 However, up to 60% of deaths in type 2 
diabetes are explained by cardiovascular disease,35 and we 
did not ﬁ nd a diﬀ erence in cardiovascular disease 
mortality between study groups. The low absolute 
number of deaths due to cardiovascular disease compared 
with deaths attributable to cancer probably indicates the 
secular decline in cardiovascular mortality in England.36 
This decline is believed to be due to both improved 
preventive treatment (primary and secondary prevention) 
and changes in lifestyle and risk factors such as the 
reduction in the prevalence of smoking. This decline 
may be steeper in the east of England, because of the 
aﬄ  uence of its population.23 As the result of this decline, 
cancers are now the most common cause of death in this 
region of England.37 Furthermore, the risk factors that 
formed part of the diabetes risk score that we used to 
deﬁ ne the study population (eg, age and obesity) also 
predispose to cancer.
To the best of our knowledge, this is the ﬁ rst trial to 
evaluate the eﬀ ect of a screening programme for type 2 
diabetes on population mortality (panel). The strengths 
of our study include the randomised design reducing 
the possibility of selection, lead, and length time bias 
and confounding seen in observational studies of 
screening.38 Trial groups were well balanced at baseline; 
the small diﬀ erence in participants’ age and the 
proportion of prescribed steroids is unlikely to have 
aﬀ ected the ﬁ ndings. The invitation list for screening 
was deﬁ ned at the outset, thereby minimising con-
tamination and selection bias due to participant 
recruitment varying by trial group. The observed ICC 
values were much smaller than anticipated, con-
tributing to tighter 95% CIs and a more robust negative 
ﬁ nding for the primary outcome. Furthermore, we 
incorporated valid outcome measure ment with mini-
mal loss to tracking and a high level of agreement for 
classiﬁ cation of cause of death. We also included a 
suﬃ  ciently large number of high-risk individuals to 
detect clinically important eﬀ ects on mortality as 
suggested by previous modelling studies. Follow-up 
Panel: Research in context
Systematic review
A modelling study12 showed that, compared with no diabetes screening, screening 
individuals every 3–5 years between the ages of 30 and 45 years would reduce the 
incidence of myocardial infarction, prevent a substantial number of deaths, and be cost 
eﬀ ective. These estimates are dependent on several key assumptions that require 
conﬁ rmation in a randomised trial. We searched PubMed for relevant articles with 
“diabetes mellitus, type 2” and “mortality” as Medical Subject Headings (MeSH) and 
the term “randomised controlled trial” in any heading, in combination with the term 
“screen*”. We placed no restriction on language, year of publication, or study quality. 
We found no published trial evidence of the eﬀ ects of a screening programme for 
diabetes on mortality.
Interpretation
Invitation to one round of screening for type 2 diabetes in high-risk individuals was not 
associated with a reduction in all-cause or diabetes-related mortality over 10 years. The 
beneﬁ ts of screening might be smaller than expected and restricted to individuals with 
detectable disease. Beneﬁ ts to the population could be increased by: detection and 
management of related cardiovascular risk factors alongside assessment of diabetes risk; 
repeated rounds of screening; and identiﬁ cation of non-attenders and strategies to 
maximise uptake of screening.
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was 10 years from practice randomisation, albeit 
slightly less from attendance for screening.
Our sample was representative of the eastern England 
population, since up to 99% of people in the UK are 
registered with a general practice. However, participating 
practices served less deprived areas than the average 
English practice. Caution should therefore be exercised 
in extrapolation of our results to more socioeconomically 
disadvantaged communities in which the disease risk 
might be higher although attendance for screening is 
likely to be lower.39 Most participants were white (the 
main  ethnic group in the region), which also limits 
generalisability. In view of the higher absolute risk of 
diabetes and its consequences among other ethnic 
groups, the beneﬁ ts of screening might be greater in 
these populations, assuming equivalent uptake. We did 
not have ethical or research governance permission to 
extract information from NHS records of individuals 
diagnosed with diabetes in the no-screening control 
group or from individuals who were clinically diagnosed 
with diabetes in the screening group following a negative 
screening test. Consequently we were unable to quantify 
lead time or compare outcomes between screen-detected 
and clinically diagnosed patients.
In conclusion, invitation to a single round of 
screening for type 2 diabetes in high-risk individuals in 
UK general practice might beneﬁ t the minority with 
detectable disease but was not associated with a 
reduction in all-cause or diabetes-related mortality over 
10 years. If population-based screening for diabetes is 
to be imple mented, it should be undertaken alongside 
assessment and management of risk factors for diabetes 
and cardiovascular disease and population level preven-
tive strategies targeting underlying determinants of 
these diseases.
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